Kawasaki Disease
Conditions
Interventions
Patients who do not respond to initial intravenous immunoglobulin (IVIG) (2 g/kg/day) with aspirin (30-50 mg/kg/day) within 48hrs will receive additional IVIG with aspirin. To patients who do not r
Sponsors
Study group for search of susceptibility genes of Kawasaki disease and implementation of genotype-based personalized medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with Kawasaki disease (KD) who are over 4 months old and under 20 years old 2.Patients nonresponsive to initial IVIG starting before the seventh day of illness and additional IVIG 3. Patients who or whose parents signed informed consent to participate in this study.
Exclusion criteria
Exclusion criteria: 1.Recurrent cases of KD 2.Patients having received initial IVIG on the eighth day or later of illness 3.Patients with coronary artery lesions before starting initial IVIG 4.Patients being afebrile before starting initial IVIG 5.Patients having received steroids and/or immunosuppressive agents within a month 6.Patients having received IVIG within 6 month 7.Patients with drug allergy or idiosyncrasy 8.Patients with other severe diseases 9.Patients with severe hepatic dysfunction when starting CyA therapy. 10.Patients with severe renal dysfunction when starting CyA therapy 11.Patients whose doctors think their participation in this study inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of coronary artery lesions abnormalities | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of fever under CyA treatment Duration to normalization of CRP levels % Neutrophils Incidence of adverse reaction | — |
Countries
Japan
Contacts
Public ContactAkira Hata
Graduate School of Medicine, Chiba University Dept.of Public Health
Outcome results
None listed